Men | Women | ||||||||
---|---|---|---|---|---|---|---|---|---|
1981-91 | 1991-00 | 2000-09 | 1991-2009 | 1981-91 | 1991-00 | 2000-09 | 1991-2009 | ||
All mental and neurological | # | 18 | 26 | 32 | 26 | 17 | 25 | 32 | 26 |
Q1 | -0.69 | -0.60 | -1.21 | -1.39 | -0.42 | -0.18 | 0.67 | 0.92 | |
Median (Q2) | 5.28 | 2.86 | 2.61 | 2.78 | 1.74 | 2.48 | 3.47 | 7.61 | |
Q3 | 9.75 | 9.20 | 6.71 | 8.44 | 7.69 | 8.66 | 7.37 | 13.15 | |
Mental and behavioural disorders | # | 27 | 33 | 34 | 33 | 25 | 33 | 34 | 33 |
Q1 | -1.64 | -1.70 | -2.71 | -1.69 | 25 | 33 | 34 | 33 | |
Median (Q2) | 0.92 | 0.85 | -1.11 | 0.93 | 0.37 | 0.40 | 0.08 | 0.86 | |
Q3 | 3.93 | 4.00 | 1.52 | 5.00 | 1.31 | 3.01 | 1.65 | 5.79 | |
Dementias | # | 17 | 23 | 23 | 20 | 17 | 23 | 26 | 23 |
Q1 | 0.05 | -0.29 | -0.54 | -0.06 | -0.70 | -0.25 | -0.67 | -0.17 | |
Median (Q2) | 0.43 | 0.26 | 0.01 | 2.60 | 0.69 | 0.53 | 0.19 | 2.40 | |
Q3 | 2.36 | 2.84 | 2.85 | 7.10 | 3.29 | 3.16 | 3.26 | 7.36 | |
Psychoactive substance use | # | 17 | 24 | 30 | 24 | 17 | 22 | 25 | 21 |
Q1 | -1.16 | -1.39 | -3.07 | -3.67 | 0.11 | -0.46 | -0.54 | -1.36 | |
Median (Q2) | 0.74 | -0.22 | -0.89 | -1.10 | 0.54 | -0.14 | -0.09 | -0.38 | |
Q3 | 2.87 | 0.97 | -0.01 | 0.13 | 0.70 | 0.20 | 0.30 | 0.08 | |
Diseases of the nervous system | # | 17 | 24 | 31 | 25 | 17 | 24 | 31 | 25 |
Q1 | -0.78 | 0.30 | 0.69 | 1.84 | -0.48 | 0.10 | 0.30 | 1.41 | |
Median (Q2) | 1.58 | 2.14 | 3.08 | 3.67 | 0.60 | 1.89 | 3.31 | 3.38 | |
Q3 | 3.37 | 3.28 | 4.61 | 7.50 | 3.02 | 3.63 | 4.86 | 6.38 | |
Meningitis | # | 27 | 32 | 33 | 33 | 27 | 32 | 30 | 30 |
Q1 | -0.55 | -0.28 | -0.49 | -0.70 | -0.50 | -0.21 | -0.17 | -0.33 | |
Median (Q2) | -0.32 | -0.05 | -0.28 | -0.39 | -0.32 | -0.11 | -0.11 | -0.22 | |
Q3 | 0.04 | 0.13 | -0.10 | -0.21 | -0.11 | 0.06 | -0.02 | -0.11 | |
Parkinson’s disease | # | 17 | 23 | 29 | 25 | 17 | 24 | 30 | 25 |
Median (Q2) | 0.41 | 0.36 | 0.59 | 1.23 | 0.18 | 0.03 | 0.24 | 0.14 | |
Q3 | 1.69 | 0.99 | 1.82 | 1.56 | 1.32 | 0.50 | 0.81 | 0.63 | |
Alzheimer’s c.a | # | 17 | 24 | 31 | 25 | 17 | 24 | 31 | 25 |
Q1 | 0.74 | -0.16 | -0.36 | 0.39 | 0.85 | 0.19 | 0.00 | 1.01 | |
Median (Q2) | 1.74 | 1.21 | 1.38 | 1.75 | 1.56 | 1.46 | 1.01 | 1.87 | |
Q3 | 3.45 | 1.94 | 2.55 | 3.46 | 3.54 | 2.39 | 2.68 | 4.70 | |
Multiple sclerosis | # | 27 | 30 | 28 | 28 | 27 | 32 | 30 | 29 |
Q1 | -0.20 | -0.18 | -0.28 | -0.39 | -0.30 | -0.37 | -0.14 | -0.33 | |
Median (Q2) | -0.05 | 0.03 | -0.06 | -0.12 | -0.02 | -0.10 | -0.01 | 0.06 | |
Epilepsy | # | 27 | 32 | 30 | 29 | 27 | 30 | 29 | 29 |
Q1 | -0.38 | -0.61 | -0.12 | -0.44 | -0.41 | -0.43 | -0.13 | -0.38 | |
Median (Q2) | 0.06 | -0.12 | 0.17 | -0.07 | -0.13 | -0.06 | 0.12 | -0.06 | |
Q3 | 0.31 | 0.27 | 0.32 | 0.22 | 0.18 | 0.14 | 0.24 | 0.15 |